Pulse Biosciences: Technology Exposed As Worthless By MedTech PHDs
from The Friendly Bear Hosted by David Capablanca, Adam Gefvert
Send us Fan Mail Pulse Biosciences [NASDAQ: PLSE] is a medical device company with one product – the CellFX system. PLSE’s history is full of failure and wasted investors’ money trying to sell its technology for skin treatments. With the same team and approach, failure is going to repeat in the company’s pivot to cardiac ablation, or the Pulsed Field Ablation (PFA) market. PLSE is years behind Boston Scientific (Farapulse) and Medtronic (Affera and PulseSelect) in the clinical studies/FDA approval process for PFA. Farapulse’s first clinical study was launched in 2018, over five years ago. While nano pulse PFA technology was patented by Farapulse, Farapulse does not use nano pulse. PLSE is developing nano pulse PFA technology, and could be infringing on Farapulse’s patents. Medtronic and Abbott also choose to not develop nano pulse because evidence shows it’s inferior to micro pulse. PLSE is desperately trying to deceive investors that they are close to commercial revenue with their ablation clamp by failing to disclose that comparable clamps had to receive PMA approval from the FDA with large clinical studies performed in order to be adopted by cardiac surgeons. Pulse Biosciences Short Report Friendly Bear University Get Profitable & Master Your Trading - Memberships & Courses Now Available David's X Profile Follow David Capablanca on X! Cobra Trading Click the link and get 33% off commissions for life as well as one month of free DAS Trader Platform Dilution Tracker Click the link and get 10% off of Dilution Tracker EdgeToTrade TraderSync Click the link for a FREE 7-day trial of the best and only trade journaling software that I use. TradeIdeas FlashSEC Click the link and get 15% off 12 months of FlashSEC Friendly Bear Conference 7 Early Bird ticket for Friendly Bear Conference 7 ft. Tom Hougaard on 10/12/26 Ortex ORTEX brings you the most timely and accurate Short interest data available Stock Analysis Pro Get unlimited access to all financial data and tools. Flash Research Find your edge with the best stock analyzer AskEdgar Book - Short Selling Master Preorder David Capablanca's book - Short Selling Master David's Instagram Subscribe for behind the scenes trading related content Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you. Support the show
Embed this episode
What this episode covers
Send us Fan Mail Pulse Biosciences [NASDAQ: PLSE] is a medical device company with one product – the CellFX system. PLSE’s history is full of failure and wasted investors’ money trying to sell its technology for skin treatments. With the same team and approach, failure is going to repeat in the company’s pivot to cardiac ablation, or the Pulsed Field Ablation (PFA) market. PLSE is years behind Boston Scientific (Farapulse) and Medtronic (Affera and PulseSelect) in the clinical studies/FDA ap...
No transcript yet.